

Yellow Fever Initiative
ONE INJECTION, FULL PROTECTION

yellow fever

Detection and investigation of serious adverse events following yellow fever vaccination

Guidance from an informal
consultation of experts

18–19 November 2008
Geneva, Switzerland



**World Health
Organization**

Yellow Fever Initiative
ONE INJECTION, FULL PROTECTION

yellow fever

Detection and investigation of serious adverse events following yellow fever vaccination

Guidance from an informal
consultation of experts

18–19 November 2008
Geneva, Switzerland



**World Health
Organization**

Acknowledgements

We would like to thank the GAVI Alliance for their financial support and all those who have contributed to preparing, drafting and revising this document.

The production of this document was coordinated by Sergio Yactayo and Rosamund Lewis with the collaboration of Anamaria Bulatovic, Alejandro Costa, Ana Estrela and William Perea.

GAR publications are available online at: www.who.int/csr/resources/publications

© World Health Organization, 2010

All rights reserved

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization.

Editorial work by Heidi Mattock

Layout and design by minimum graphics

Drawings (AnnexVI) by ACID-Solutions

Printed by the WHO Document Production Services, Geneva, Switzerland

Contents

Abbreviations and acronyms	vi
Preface	vii
Background	1
Purpose	2
Who will use this operational guide?	2
Defining the problem	3
The need for surveillance of serious AEFIs	3
Objectives	4
Methods	4
SECTION 1. Field surveillance and data collection for serious adverse events following yellow fever immunization: peripheral level	5
1.1 Case detection based on existing notification systems	5
1.2 Classification: serious versus non-serious	5
1.3 Reporting of adverse events following immunization	6
SECTION 2. Surveillance and primary investigation of serious adverse events: intermediate and referral facilities	9
2.1 Active case-finding	9
2.1.1 Enhanced surveillance in intermediate and referral facilities	9
2.1.2 Surveillance system units and mobile teams: definition and role	9
2.2 Classification of AEFI	11
2.2.1 Classification by severity	11
2.2.2 Classification by cause	11
2.2.3 Classification of an AEFI as a serious vaccine reaction	11
2.3 Investigation	12
2.4 Case management	12
SECTION 3. Further investigation, processing and analysis of data on serious AEFIs: intermediate and central level	15
3.1 Investigation of serious “vaccine reaction” following yellow fever vaccination	15
3.2 Clinical syndromes and physical findings	15
3.2.1 Yellow fever vaccine-associated viscerotropic disease	15
3.2.2 Yellow fever vaccine-associated neurological disease	16
3.2.3 Severe hypersensitivity reactions following vaccination against yellow fever	16
3.2.4 Other serious adverse events	16
3.3 Information and samples required for all serious vaccine reactions	16

SECTION 4. Final classification of serious adverse events following immunization against yellow fever into “suspect”, “probable” and “confirmed” cases: central and international level	19
4.1 National expert committee: central and international level	19
4.1.1 Roles and responsibilities of the national yellow fever vaccine adverse events monitoring expert committee	19
4.1.2 National yellow fever vaccine adverse events monitoring expert committee	20
4.1.3 Meetings of the expert committee	20
4.2 Investigation by the reference laboratory: international level	21
4.2.1 Differential diagnosis	21
4.2.2 Standard operating procedures for collection, storage and transport of samples to be sent to a WHO reference laboratory	21
4.2.3 Standard operating procedures for collection, storage and transport of autopsy samples to be sent to a WHO reference laboratory	21
4.2.4 Identification of the international reference laboratory	23
References	25
Bibliography	26
List of participants	27
Annexes	
Annex I: Expertise necessary for effective immunization safety	31
Annex II: Notification report for an adverse event following immunization against yellow fever (YF-AEFI)	32
Annex III: Evaluation form for a serious adverse event following immunization against yellow fever (YF-AEFI)	34
Annex IV: Case definitions of viscerotropic and neurological adverse events following immunization against yellow fever, according to VAERS	37
Annex V: Detecting a serious adverse event following immunization against yellow fever (YF-AEFI)	42
Annex VI: Autopsy specimens to be taken in the event of death after an adverse event following immunization against yellow fever (YF-AEFI)	44
Annex VII: Specimens to be taken for diagnosis of a suspected adverse event following immunization against yellow fever (YF-AEFI)	45
Annex VIII: Detection of a serious adverse event following immunization against yellow fever (YF-AEFI): warning signs	46
Annex IX: Differential diagnosis of adverse events involving viscerotropic and neurological disease following immunization against yellow fever (YF-AEFI)	47
Annex X: Reference laboratory: sample collection, storage and transport and yellow fever specific investigations	48
Annex XI: Patient admission flowchart: serious adverse event following immunization (AEFI) against yellow fever identified as a possible vaccine reaction	51

List of Boxes, Figures and Tables

Box 1.	Classification of an adverse event following immunization (AEFI) as “serious” or “non-serious”	5
Box 2.	Tools for case detection at the peripheral health centre	6
Figure 1.	Surveillance and classification of adverse events following immunization (AEFI): tasks to be accomplished, by administrative level	7
Figure 2.	Algorithm for early detection of adverse effects following immunization (AEFI) during a campaign of mass vaccination against yellow fever: peripheral level	8
Figure 3.	Decision tree for serious adverse events following immunization (AEFI) against yellow fever: intermediate level	10
Box 3.	Role of surveillance system units and mobile teams	11
Box 4.	Tools for surveillance of adverse events following immunization (AEFI): intermediate level	12
Box 5.	Differential diagnosis: main diseases to be ruled out	12
Table 1.	Recommended laboratory tests for suspected serious adverse events following immunization against yellow fever	13
Table 2.	Recommendations for collection of specimens to be sent to a WHO reference laboratory	22

Abbreviations

ADEM	acute disseminated encephalomyelitis
AEFI	adverse events following immunization
ALT	alanine aminotransferase (also known as serum glutamic-pyruvic transaminase, SGPT)
AND	associated with neurological disease
AST	aspartate aminotransferase (also known as serum glutamic-oxaloacetic transaminase, SGOT)
AVD	associated with viscerotropic disease
BCG	Bacille-Calmette-Guérin
CSF	cerebrospinal fluid
CMV	cytomegalovirus
CPK	creatine phosphokinase
EBV	Epstein-Barr virus
ECG	electrocardiogram
EEG	electroencephalogram
ELISA	enzyme-linked immunosorbent assay
EMG	electromyography
EPI	Expanded Programme on Immunization
ERI	Epidemic Readiness and Intervention Team
GAVI	The GAVI Alliance (Global Alliance for Vaccines and Immunization)
HIV	human immunodeficiency virus
ICD	International Classification of Diseases

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_29417

